Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

IDEAYA closes $94mm Series B round

Executive Summary

Oncology firm IDEAYA Biosciences Inc. raised $94mm through a crossover Series B round co-led by Nextech Invest, 6 Dimensions Capital, and Perceptive Advisors. Additional new investors BVF Partners, GV, Roche Venture Fund, Tavistock Group's Boxer Capital, and Driehaus Capital Management also participated, along with returning backers 5AM Ventures, Canaan Partners, Celgene, WuXi Healthcare Ventures, and Alexandria Venture Investments. Nextech and 6 Dimensions join the company's board, while BVF, GV, and Roche Venture Fund take observer seats. IDEAYA is developing next-gen biomarker-enabled synthetic lethality candidates for cancer, and will use the Series B proceeds to advance its pipeline into clinical trials.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies